Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $62 from $51 and keeps an Overweight rating on the shares. The firm says Yutrepia appears to be disrupting the pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease market, and Wells anticipates this level of growth continues through Q2. The firm is also lifting its near-term Yutrepia estimate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Regulatory Hurdles and Competitive Pressures Threaten Liquidia’s YUTREPIA and L606 Prospects
- Liquidia Technologies Rides YUTREPIA Surge in Earnings Call
- Liquidia price target raised to $60 from $57 at Jefferies
- Midday Fly By: Dream Finders offers to buy Beazer, Fox reports Q3 beat
- Liquidia reports Q1 EPS 52c, consensus 41c